Author:
Okude Miho,Suzuki Kenji,Naito Asami,Ebashi Akio,Kusama Tomoka,Kiyotaki Junichi,Akashi Yusaku,Kiyasu Yoshihiko,Kurihara Yoko,Notake Shigeyuki,Takanashi Masaki,Setoyama Tomokazu,Kawakami Yasushi,Suzuki Hiromichi
Abstract
AbstractWe designed and developed two new types of hydrogen fuel cell (HFC) buses (motorcoach and minibus) with a mobile laboratory system. Feasibility studies have been performed for mobile laboratory testing, particularly for the laboratory performance of COVID-19 RT-PCR (PCR). We evaluated the driving range capability, PCR sample size capacity, turnaround time (TAT), and analytical performance for the detection of SARS-CoV-2. Saliva samples were used for the current study, and the analytical performance was compared with that of the reference PCR. The estimated driving range and sample size capacity of the HFC and HFC minibus were 432 km and 2847 samples, respectively, for the HFC motorcoach and 313 km and 1949 samples for the HFC minibus. For the TAT, the median time between sample submission and completion of PCR was 86 min for the motorcoach and 76 min for the minibus, and the median time between sample submission and electronic reporting of the result to each visitor was 182 min for the motorcoach and 194 min for the minibus. A secondary analysis of 1574 HFC mobile laboratory testing samples was conducted, and all negative samples were found to be negative by reference PCR. Furthermore, all samples were confirmed to be positive by reference PCR or other molecular examinations.
Funder
Precision System Science Co., Ltd.,
TOYOBO Co., Ltd.,
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Dinnes, J. et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 7, CD013705 (2022).
2. Hanson, K. E. et al. The infectious diseases Society of America guidelines on the diagnosis of COVID-19: Antigen testing. Clin. Infect. Dis. 23, 557 (2021).
3. Akashi, Y. et al. Clinical performance of the cobas Liat SARS-CoV-2 & influenza A/B assay in nasal samples. Mol. Diagn. Ther. 26, 323–331 (2022).
4. Akashi, Y. et al. Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus. J. Infect. Chemother. 25, 578–583 (2019).
5. Dinnes, J. et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst. Rev. 3, CD013705 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献